FI105812B - Menetelmä terapeuttisesti käyttökelpoisten indolijohdannaisten valmistamiseksi - Google Patents

Menetelmä terapeuttisesti käyttökelpoisten indolijohdannaisten valmistamiseksi Download PDF

Info

Publication number
FI105812B
FI105812B FI931667A FI931667A FI105812B FI 105812 B FI105812 B FI 105812B FI 931667 A FI931667 A FI 931667A FI 931667 A FI931667 A FI 931667A FI 105812 B FI105812 B FI 105812B
Authority
FI
Finland
Prior art keywords
alkyl
indole
aryl
ylmethyl
hydrogen
Prior art date
Application number
FI931667A
Other languages
English (en)
Finnish (fi)
Swedish (sv)
Other versions
FI931667A (fi
FI931667A0 (fi
Inventor
Martin James Wythes
John Eugene Macor
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24393510&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI105812(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of FI931667A publication Critical patent/FI931667A/fi
Publication of FI931667A0 publication Critical patent/FI931667A0/fi
Application granted granted Critical
Publication of FI105812B publication Critical patent/FI105812B/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Electroluminescent Light Sources (AREA)
  • Lasers (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
FI931667A 1990-10-15 1993-04-14 Menetelmä terapeuttisesti käyttökelpoisten indolijohdannaisten valmistamiseksi FI105812B (fi)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US59792890A 1990-10-15 1990-10-15
US59792890 1990-10-15
US9107194 1991-10-08
PCT/US1991/007194 WO1992006973A1 (en) 1990-10-15 1991-10-08 Indole derivatives

Publications (3)

Publication Number Publication Date
FI931667A FI931667A (fi) 1993-04-14
FI931667A0 FI931667A0 (fi) 1993-04-14
FI105812B true FI105812B (fi) 2000-10-13

Family

ID=24393510

Family Applications (1)

Application Number Title Priority Date Filing Date
FI931667A FI105812B (fi) 1990-10-15 1993-04-14 Menetelmä terapeuttisesti käyttökelpoisten indolijohdannaisten valmistamiseksi

Country Status (33)

Country Link
EP (1) EP0592438B1 (hu)
JP (2) JP2575272B2 (hu)
KR (1) KR0179053B1 (hu)
CN (1) CN1039322C (hu)
AT (1) ATE157361T1 (hu)
AU (1) AU651637B2 (hu)
BG (1) BG61975B1 (hu)
BR (2) BR9106978A (hu)
CA (1) CA2091562C (hu)
DE (3) DE10299004I2 (hu)
DK (1) DK0592438T5 (hu)
EG (1) EG20224A (hu)
ES (1) ES2104733T3 (hu)
FI (1) FI105812B (hu)
GR (1) GR3025087T3 (hu)
HU (2) HU225055B1 (hu)
IE (1) IE913555A1 (hu)
IL (3) IL115117A (hu)
LU (1) LU90902I2 (hu)
MX (1) MX9101606A (hu)
MY (1) MY111683A (hu)
NL (1) NL300070I2 (hu)
NO (3) NO305121B1 (hu)
NZ (2) NZ240217A (hu)
OA (1) OA09874A (hu)
PL (3) PL169987B1 (hu)
PT (1) PT99218B (hu)
RO (1) RO111767B1 (hu)
RU (1) RU2095360C1 (hu)
SG (1) SG54270A1 (hu)
WO (1) WO1992006973A1 (hu)
YU (1) YU48088B (hu)
ZA (1) ZA918156B (hu)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545644A (en) * 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5559129A (en) * 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5559246A (en) * 1990-10-15 1996-09-24 Pfizer Inc. Indole derivatives
US5607951A (en) * 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5578612A (en) * 1990-10-15 1996-11-26 Pfizer Inc. Indole derivatives
ES2143992T3 (es) * 1991-11-25 2000-06-01 Pfizer Derivados de 5-(hetero- o carbociclilamino)-indol, su preparacion y uso como 5-ht1 agonistas.
TW288010B (hu) * 1992-03-05 1996-10-11 Pfizer
KR0179072B1 (ko) * 1992-04-07 1999-03-20 알렌 제이. 스피겔 5-ht1 작동약으로서의 인돌 유도체
GB9207930D0 (en) * 1992-04-10 1992-05-27 Pfizer Ltd Indoles
KR0179074B1 (ko) * 1992-04-10 1999-03-20 알렌 제이. 스피겔 5-ht1 작용물질로서의 아실아미노인돌 유도체
GB9208161D0 (en) * 1992-04-14 1992-05-27 Pfizer Ltd Indoles
GB9210400D0 (en) * 1992-05-15 1992-07-01 Merck Sharp & Dohme Therapeutic agents
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
TW251284B (hu) * 1992-11-02 1995-07-11 Pfizer
FR2701026B1 (fr) * 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
IT1271352B (it) * 1993-04-08 1997-05-27 Boehringer Ingelheim Italia Derivati dell'indolo utili nel trattamento dei disturbi del sistema nervoso centrale
CN1121348A (zh) * 1993-04-22 1996-04-24 辉瑞研究及发展公司 吲哚衍生物作为5-ht1类激动剂用于治疗周期性偏头痛
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.
ES2070772B1 (es) * 1993-08-09 1996-02-16 Pfizer Derivados de acilaminoindol
ATE170836T1 (de) * 1993-08-31 1998-09-15 Pfizer 5-arylindolderivate
WO1996004266A2 (de) * 1994-08-03 1996-02-15 Asta Medica Aktiengesellschaft Indol-, indazol-, pyridopyrrol- und pyridopyrazol-derivate mit antiasthmatischer, antiallergischer, entzündungshemmender und immunmodulierender wirkung
GB9417310D0 (en) * 1994-08-27 1994-10-19 Pfizer Ltd Therapeutic agents
GB9420529D0 (en) * 1994-10-12 1994-11-30 Pfizer Ltd Indoles
AU726560B2 (en) * 1994-10-12 2000-11-09 Pfizer Research And Development Company, N.V./S.A. Use of indole derivatives for the treatment of various diseases
CA2213241C (en) * 1994-10-12 2001-07-10 Pfizer Research And Development Company, N.V./S.A. Indole derivative for the treatment of migraine
GB9424471D0 (en) * 1994-12-03 1995-01-18 Pfizer Ltd Treatment of emesis
PL322843A1 (en) * 1995-03-20 1998-02-16 Lilly Co Eli 5-substituted 3-91,2,3,6-tetrahydropyridin-4-yl)- and 3-9piperydin-4-4-yl0-1h-indoles nevel 5-htif natagonists
GB9510223D0 (en) * 1995-05-20 1995-07-19 Pfizer Ltd Therapeutic agent
US5945118A (en) * 1995-09-29 1999-08-31 Pfizer Inc Indole derivative for the treatment of migraine
GB9714383D0 (en) * 1997-07-08 1997-09-10 Pfizer Ltd Improved process
WO1999053956A1 (fr) * 1998-04-16 1999-10-28 Yamanouchi Pharmaceutical Co., Ltd. Remedes contre l'obesite
GB9816556D0 (en) * 1998-07-30 1998-09-30 Pfizer Ltd Therapy
US5994352A (en) * 1998-11-13 1999-11-30 Pfizer Inc. 5-arylindole derivatives
GB9825988D0 (en) 1998-11-27 1999-01-20 Pfizer Ltd Indole derivatives
GB9922963D0 (en) * 1999-09-28 1999-12-01 Pfizer Ltd Polymorphic salt
JP2000336074A (ja) 1999-03-24 2000-12-05 Sumitomo Chem Co Ltd ［２−（アリールスルホニル）エテニル］ベンゼン誘導体の製造方法
GB9915231D0 (en) 1999-06-29 1999-09-01 Pfizer Ltd Pharmaceutical complex
WO2001016101A1 (fr) * 1999-08-26 2001-03-08 Fujisawa Pharmaceutical Co., Ltd. Procede de preparation de derives de l'indole ou de leurs sels
GB9923314D0 (en) 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
FR2799463B1 (fr) * 1999-10-12 2004-04-16 Adir Nouveaux composes cyano-indoles inhibiteurs de recapture de serotonine, leur procede de preparation et ces compositions pharmaceutiques qui les contiennent
GB0031094D0 (en) * 2000-12-20 2001-01-31 Pfizer Ltd New Process
US20030166704A1 (en) 2000-12-20 2003-09-04 Pfizer Inc. New process
US8329734B2 (en) 2009-07-27 2012-12-11 Afgin Pharma Llc Topical therapy for migraine
UA76483C2 (en) 2001-08-15 2006-08-15 Upjohn Co Crystalline form of malic acid salt of n-|2-(diethylamino)ethyl|-5-|(5-fluoro -2--oxo-3n-indol-3-ylidene)methyl]-2,4- dimelhyl-1n-pyrrole-3-carboxamide (variants), a method for preparing and compositions thereof
US7132549B2 (en) 2003-05-30 2006-11-07 Pfizer Inc. Process
GB0312478D0 (en) * 2003-05-30 2003-07-09 Pfizer Ltd Improved process
US20070065463A1 (en) 2003-06-20 2007-03-22 Ronald Aung-Din Topical therapy for the treatment of migranes, muscle sprains, muscle spasms, spasticity and related conditions
ATE456557T1 (de) 2005-06-15 2010-02-15 Pfizer Ltd Substituierte arylpyrazole zur verwendung gegen parasiten
US7645786B2 (en) 2005-06-15 2010-01-12 Pfizer Inc. Substituted arylpyrazoles
WO2006079999A2 (en) * 2006-04-09 2006-08-03 Barth Frederik H Induction of a novel state of mind with a 5-ht2a agonist and a nmda antagonist
US20090299077A1 (en) * 2008-05-22 2009-12-03 Vinod Kumar Kansal Salts of (R)-5-(2phenylsulphonylethenyl)-3-(N-methylpyrrolidin-2-ylmethyl)-1H-indole, 5-bromo-3-[(R)-1-methyl-pyrrolidin-2-ylmethyl]-1H-indole and of eletriptan
US8592424B2 (en) 2008-06-30 2013-11-26 Afgin Pharma Llc Topical regional neuro-affective therapy
EP2149573A1 (en) * 2008-08-01 2010-02-03 Laboratorios Del. Dr. Esteve, S.A. Substituted indole sulfonamide compounds their preparation and use as medicaments
IT1393700B1 (it) 2009-04-22 2012-05-08 F S I Fabbrica Italiana Sint Sintesi di 3-{[(2r)-1-metilpirrolidin-2-il]metil}-5-[2-(fenilsulfonil)etil]-1h-indolo
WO2011004391A2 (en) 2009-06-25 2011-01-13 Matrix Laboratories Ltd An improved process for the preparation of eletriptan and its salt thereof
WO2011024039A1 (en) * 2009-08-25 2011-03-03 Ramesh Babu Potluri Synthesis of novel 5-(2-(phenylsulfonyl)ethyl)-1h-indole derivatives
WO2011089614A1 (en) * 2010-01-19 2011-07-28 Sms Pharmaceuticals Limited PROCESS FOR PREPARING ELETRIPTAN HYDROBROMIDE HAVING α-FORM
CN102606426B (zh) * 2012-03-02 2014-05-21 王仲彦 踏步健身发电装置
WO2014063752A1 (en) 2012-10-26 2014-05-01 Synthon Bv Process for making crystalline form alpha of eletriptan hydrobromide
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
CN103408535B (zh) * 2013-08-13 2016-03-02 张家港威胜生物医药有限公司 一种依来曲普坦中间体-5-溴-3-(n-甲基吡咯啉-2-基甲基)-1h-吲哚合成工艺
US10383816B2 (en) 2015-03-02 2019-08-20 Afgin Pharma, Llc Topical regional neuro-affective therapy with cannabinoid combination products
US20160256410A1 (en) 2015-03-02 2016-09-08 Afgin Pharma, Llc Topical regional neuro-affective therapy in mammals with cannabinoids
JP2019502761A (ja) 2016-01-21 2019-01-31 ラボラトリオス レヴィ エセエレ （（ｒ）−３−［（−１−メチルピロリジン−２−イル）メチル］−５−（２−フェニルスルホニルエチル）−１ｈ−インドールを作製する方法
CN106065008B (zh) * 2016-06-16 2018-06-05 黑龙江中医药大学 一种具有改善睡眠作用的吲哚-2-酰胺类化合物及其应用
US20180049994A1 (en) 2016-08-16 2018-02-22 Afgin Pharma, Llc Topical regional neuro-affective therapy with caryophyllene
TR201616365A1 (tr) 2016-11-14 2018-05-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Deksketoprofen ve eletri̇ptanin oral farmasöti̇k kompozi̇syonlari
TR201619983A2 (tr) 2016-12-29 2018-07-23 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Di̇klofenak ve eletri̇ptanin farmasöti̇k formülasyonlari
KR102129947B1 (ko) 2018-06-08 2020-07-03 김종창 콘크리트 타설을 위한 입체형 와이어 메쉬
EP3766483A1 (en) 2019-07-19 2021-01-20 BioPharma Synergies, S. L. Orodispersible powder composition comprising a triptan
WO2021148868A1 (en) 2020-01-22 2021-07-29 Technophage, Investigação E Desenvolvimento Em Biotecnologia, S.A. Eletriptan hydrobromide for treatment of spinal cord injury and improvement of locomotor function
WO2023150547A2 (en) * 2022-02-01 2023-08-10 Caamtech, Inc. Psychedelic compounds and their therapeutic uses

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL74527C (hu) *
US2773875A (en) * 1952-03-28 1956-12-11 Hoffmann La Roche Indole derivatives and method for producing same
GB886684A (en) * 1957-09-17 1962-01-10 Upjohn Co Improvements in or relating to heterocyclic compounds and the manufacture thereof
GB851780A (en) * 1958-02-25 1960-10-19 Rhone Poulenc Sa New indole derivatives
US3037031A (en) * 1959-08-04 1962-05-29 Warner Lambert Pharmaceutical Derivatives of 3-(2-aminoalkyl)-5-indolol and process therefor
GB893707A (en) * 1960-03-01 1962-04-11 Roche Products Ltd Novel tryptamine derivatives and a process for the manufacture thereof
GB966562A (en) * 1961-04-06 1964-08-12 Parke Davis & Co Amine compounds and means of producing the same
BE889931A (fr) * 1980-08-12 1982-02-11 Glaxo Group Ltd Derives indoliques, leur preparation et leurs applications en tant que medicaments
ZW19381A1 (en) * 1980-08-12 1983-03-09 Glaxo Group Ltd Heterocyclic compounds
US4803218A (en) * 1982-09-29 1989-02-07 Mcneilab, Inc. 3-aminoalkyl-1H-indole-5-urea and amide derivatives
GB8600397D0 (en) * 1986-01-08 1986-02-12 Glaxo Group Ltd Chemical compounds
GB8719167D0 (en) * 1987-08-13 1987-09-23 Glaxo Group Ltd Chemical compounds
GB8819024D0 (en) * 1988-08-10 1988-09-14 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
YU48088B (sh) 1997-01-08
BG61975B1 (bg) 1998-11-30
LU90902I2 (fr) 2002-06-26
PL168919B1 (pl) 1996-05-31
CN1039322C (zh) 1998-07-29
RO111767B1 (ro) 1997-01-30
JPH093063A (ja) 1997-01-07
CA2091562C (en) 2001-03-27
CA2091562A1 (en) 1992-04-16
BR9106978A (pt) 1993-09-28
ES2104733T3 (es) 1997-10-16
NO931378L (no) 1993-04-14
NZ270675A (en) 1997-07-27
DE10299004I1 (de) 2002-05-08
DE69127468D1 (de) 1997-10-02
NO2001019I1 (no) 2001-12-03
EG20224A (en) 1997-12-31
WO1992006973A1 (en) 1992-04-30
DE10299004I2 (de) 2006-03-16
PT99218B (pt) 1999-04-30
NO305121B1 (no) 1999-04-06
IL99701A (en) 1996-10-31
HU9301098D0 (en) 1993-07-28
OA09874A (en) 1994-09-15
JP2575272B2 (ja) 1997-01-22
IL99701A0 (en) 1992-08-18
FI931667A (fi) 1993-04-14
RU2095360C1 (ru) 1997-11-10
DE69127468T2 (de) 1998-01-02
SG54270A1 (en) 1998-11-16
IL115117A (en) 1996-11-14
EP0592438A1 (en) 1994-04-20
FI931667A0 (fi) 1993-04-14
GR3025087T3 (en) 1998-01-30
ATE157361T1 (de) 1997-09-15
PT99218A (pt) 1992-09-30
CN1062529A (zh) 1992-07-08
BR1100080A (pt) 2000-06-06
JP2677777B2 (ja) 1997-11-17
JPH05507288A (ja) 1993-10-21
NO985607L (no) 1998-12-01
NO985607D0 (no) 1998-12-01
IE913555A1 (en) 1992-04-22
YU165391A (sh) 1994-01-20
EP0592438B1 (en) 1997-08-27
PL170330B1 (pl) 1996-11-29
AU8950491A (en) 1992-05-20
PL169987B1 (en) 1996-09-30
DK0592438T5 (da) 1999-12-06
MX9101606A (es) 1992-06-05
NL300070I2 (nl) 2002-03-01
NO931378D0 (no) 1993-04-14
DE9190141U1 (de) 1993-07-15
AU651637B2 (en) 1994-07-28
ZA918156B (en) 1993-04-14
MY111683A (en) 2000-11-30
KR0179053B1 (ko) 1999-03-20
HUT64326A (en) 1993-12-28
NL300070I1 (nl) 2002-02-01
IL115117A0 (en) 1995-12-08
BG97632A (bg) 1994-03-31
DK0592438T3 (da) 1997-09-29
HU225055B1 (en) 2006-05-29
NZ240217A (en) 1995-05-26

Similar Documents

Publication Publication Date Title
FI105812B (fi) Menetelmä terapeuttisesti käyttökelpoisten indolijohdannaisten valmistamiseksi
US5545644A (en) Indole derivatives
US5578612A (en) Indole derivatives
KR100857671B1 (ko) 화학적 화합물
FI107158B (fi) Menetelmä kondensoitujen indolikarboksylaatti- ja indolikarboksiamidijohdannaisten valmistamiseksi
NL1026438C2 (nl) Nieuwe verbindingen.
WO2014002052A1 (en) Pyrrolidine derivatives and their use as complement pathway modulators
ZA200603181B (en) 3-(4-aminophenyl) thienopyrimid-4-one derivatives as MCH R1 antagonists for the treatment of obesity, diabetes, depression and anxiety
US20040157818A1 (en) Cxcr4-antagonistic drugs composed of nitrogen-containing compound
US5559129A (en) Indole derivatives
KR0183396B1 (ko) 3-아릴카르보닐-1-아미노알킬-1h-인돌류,이를 함유하는 항녹내장 조성물 및 이의 제조방법
TW199860B (hu)
US5559246A (en) Indole derivatives
EP0563916A1 (en) (1H-Indol-1-yl)-2-(amino)acetamides and related (1H-indol-1-yl)-(aminoalkyl)amides, intermediates and a process for their preparation and their use as medicaments
JP6844822B2 (ja) 疼痛に対して活性を有する置換モルホリン誘導体
JP6884973B2 (ja) 疼痛に対して活性を有するオキサジアザスピロ化合物
WO1997045426A1 (en) Azetidine, pyrrolidine and piperidine derivatives as 5-ht1d receptor agonists
CA2350089C (en) Indole derivatives
NZ612899B2 (en) Indole compounds or analogues thereof useful for the treatment of age-related macular degeneration (amd)

Legal Events

Date Code Title Description
SPCG Supplementary protection certificate granted

Spc suppl protection certif: L191

Extension date: 20151213

MA Patent expired